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Cocrystallization represents a low risk, low cost approach with the most potential for achieving the desired therapeutic outcome. The active pharmaceutical ingredient (API) in this crystal engineering approach remains lithium, which is already FDA-approved with a long history of use in the medical field. Our researchers have synthesized and evaluated two unique and previously unexplored cocrystals: lithium salicylate and lithium lactate.
USF researchers have determined that these lithium salts exhibit profoundly different plasma and brain pharmacokinetics compared to the more common FDA approved salt, lithium carbonate. They produce elevated plasma and brain lithium levels out to 48 hours while attenuating the spike associated with the toxic side effects of current lithium therapeutics. These salts are ideal for development of the next generation of lithium therapeutics.
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